Innogenetics

Innogenetics NV develops and sells diagnostic products for treatment management and patient health. Its diagnostics business focuses on developing products for infectious diseases, genetic testing, tissue typing, neurodegeneration, and oncology. Its products in the infectious disease field include screening and confirmation tests for HIV, HCV, HTLV, and syphilis; genotyping tests for hepatitis B virus (HBV), human papillomavirus, and mycobacterium sp; as well as drug resistance tests for TB and HBV. Innogenetics also provides genetic testing products, including tests for cystic fibrosis and MBL2 and APO E gene variants associated with genetic risks. Tissue typing tests are used to determine HLA types, and neurodegenerative disease products include tests for Alzheimer's disease. In the field of oncology, the company distributes diagnostic products from AdnaGen AG for breast and colon cancer. Its therapeutic business is committed to developing therapeutic vaccines for infectious diseases caused by hepatitis C, hepatitis B, and human papillomavirus. The company’s therapeutic products include the multi-epitope vaccine candidate GNI-102, which is currently in Phase I clinical trials for HBV. GNI-104 is a neutralizing human monoclonal antibody against HCV; GNI-105 is a multi-epitope vaccine candidate for HPV.